1 line
9.7 KiB
Text
1 line
9.7 KiB
Text
|
{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,5,26]],"date-time":"2023-05-26T04:21:09Z","timestamp":1685074869987},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T00:00:00Z","timestamp":1681948800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T00:00:00Z","timestamp":1681948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Leipzig"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Strahlenther Onkol"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1007\/s00066-023-02084-8","type":"journal-article","created":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T15:21:41Z","timestamp":1682004101000},"page":"604-606","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Re-irradiation and Bevacizumab\u00a0\u2013 active combination for treatment of recurrent glioblastoma","Re-Bestrahlung und Bevacizumab\u00a0\u2013 wirksame Partner bei rezidiviertem Glioblastom"],"prefix":"10.1007","volume":"199","author":[{"given":"Clemens","family":"Seidel","sequence":"first","affiliation":[]},{"given":"Nils H.","family":"Nicolay","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2023,4,20]]},"reference":[{"issue":"1","key":"2084_CR1","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.ijrobp.2008.10.043","volume":"75","author":"PH Gutin","year":"2009","unstructured":"Gutin\u00a0PH, Iwamoto\u00a0FM, Beal\u00a0K et\u00a0al (2009) Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 75(1):156\u2013163. https:\/\/doi.org\/10.1016\/j.ijrobp.2008.10.043","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"2084_CR2","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s11060-014-1394-5","volume":"117","author":"M Flieger","year":"2014","unstructured":"Flieger\u00a0M, Ganswindt\u00a0U, Schwarz\u00a0SB et al (2014) Re-irradiation and bevacizumab in recurrent high-grade glioma: an effective treatment option. J\u00a0Neurooncol 117(2):337\u2013345. https:\/\/doi.org\/10.1007\/s11060-014-1394-5","journal-title":"J Neurooncol"},{"issue":"4","key":"2084_CR3","doi-asserted-by":"publisher","first-page":"989","DOI":"10.3171\/2015.4.JNS15194","volume":"124","author":"LM Sagberg","year":"2016","unstructured":"Sagberg\u00a0LM, Solheim\u00a0O, Jakola\u00a0AS (2016) Quality of survival the 1st year with glioblastoma: a\u00a0longitudinal study of patient-reported quality of life. J\u00a0Neurosurg 124(4):989\u2013997. https:\/\/doi.org\/10.3171\/2015.4.JNS15194","journal-title":"J Neurosurg"},{"issue":"10","key":"2084_CR4","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1016\/j.ejca.2015.03.025","volume":"51","author":"L Dirven","year":"2015","unstructured":"Dirven\u00a0L, van den Bent\u00a0MJ, Bottomley\u00a0A et al (2015) The impact of bevacizumab on health-related quality of life in patients treated for recurrent glioblastoma: results of the randomised controlled phase 2 BELOB trial. Eur J Cancer 51(10):1321\u20131330. https:\/\/doi.org\/10.1016\/j.ejca.2015.03.025","journal-title":"Eur J Cancer"},{"issue":"4","key":"2084_CR5","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1158\/1078-0432.CCR-06-2309","volume":"13","author":"JJ Vredenburgh","year":"2007","unstructured":"Vredenburgh\u00a0JJ, Desjardins\u00a0A, Herndon\u00a0JE et\u00a0al (2007) Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13(4):1253\u20131259. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-2309","journal-title":"Clin Cancer Res"},{
|